The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Dr Miruna Sasu Discusses the Transformative Power of Real-world Data

May 18th 2022, 11:07am


Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses the medicines discovery process and how real-world data can be used to evaluate patient and tumor response to treatment regimens.

A Look at the Current, Future State of Cell and Gene Therapies in the United States

May 12th 2022, 4:38pm


Experts evaluated the future of cell and gene therapies in the United States and offered insights on potential value-based payment models for these treatments.

Pressure-Induced Increase in PD-L1 Expression May Dull Effect of CAR T-Cell Therapy

May 10th 2022, 12:09pm


The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also suggest that adding PD-1/PD-L1 inhibitors to CAR T-cell therapy could help address this.

Researchers Call for Better Detection of, Intervention for AEs From PD‐1/PD‐L1 Treatment

May 7th 2022, 3:01pm


The researchers highlighted a need for the detection of more relevant markers and guidance on how to treat adverse events (AEs), the types and severity of which vary based on disease type.

Moffitt Team Finds Potential CAR T Target for Solid Tumors

May 5th 2022, 7:35pm


So far, the wonders of chimeric antigen receptor (CAR) T-cell therapy have only been seen in blood cancers. Investigators at Moffitt Cancer Center report findings that show a potential target in solid tumors.

Review Highlights Progress and Potential in Immunotherapy Plus Radiotherapy for Cancer Treatment

April 26th 2022, 4:15pm


With further research, a selection of combination therapies could increase patient response in various cancer types.

NCCN Recommends Pacritinib for Treatment of Myeloproliferative Neoplasms

April 18th 2022, 3:51pm


Pacritinib is now included as a recommended treatment for myeloproliferative neoplasms with specificity for JAK2 and IRAK1 in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

Evidence, Support, and Education Needed to Drive Precision Oncology, Accenture’s Bogdan Says

April 14th 2022, 12:34pm


Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.

AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC

April 12th 2022, 7:26pm


Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.

Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC

April 8th 2022, 10:40pm


Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.